琥珀酸美托洛尔缓释片治疗轻中度原发性高血压的临床研究

目的观察选择性β1受体阻滞剂琥珀酸美托洛尔缓释片(Betaloc ZOK,简称倍他洛克缓释片)治疗轻中度原发性高血压的疗效和安全性。方法30例轻中度原发性高血压患者服用倍他洛克缓释片47.5~95 mg/d 8周。治疗前后测量坐位血压,监测肝肾功能、血糖、血脂,记录药物不良反应。结果治疗8周后,收缩压和舒张压分别下降(13.70±17.70)mm Hg和(11.03±9.85)mm Hg(P均<0.001),26/30例患者血压<140/90 mm Hg,降压达标率为86.7%。心率、肝功能和血糖、血脂指标治疗前后差异无统计学意义。血肌酐显著下降[(0.92±0.2)mg/dlvs.(0.79±0.20)mg/dl,P<0.001]。结论倍他洛克缓释片能有效治疗轻中度原发性高血压,无明显不良反应,患者依从性良好。

Clinical study of extended-release metoprolol succinate in treatment of patients with mild to moderate primary hypertension

Objective To observe the efficacy and safety of extended-release metoprolol succinate(Betaloc ZOK,a new-style repository preparation of selective beta1-adrenergic blocker) in treatment of patients with mild to moderate primary hypertension.Methods Thirty patients of mild to moderate primary hypertension were given 47.5-95 mg/d Betaloc ZOK for 8 weeks.Blood pressure,renal function,hepatic function,blood glucose and lipid were measured,and adverse events were recorded before and after treatment.Results After treatment,systolic and diastolic blood pressure were decreased by(13.70±17.7)mm Hg and(11.03±9.85)mm Hg respectively(P<0.001).There were 86.7% patients with blood pressure less than 140/90 mm Hg.Heart rate,hepatic function,blood glucose and lipid did not change significantly before and after treatment.However,serum creatinine level reduced significantly after treatment compared with before(0.79±0.20mg/dl vs.0.92±0.2 mg/dl,P<0.001).Conclusions Betaloc ZOK can effectively treat the patients of mild to moderate primary hypertension with good compliance and no obvious adverse events.